DZL researchers at the ARCN site have modified a naturally occurring anti-inflammatory messenger molecule to prolong its activity in the body. In a mouse model, the modified version of interleukin-37 significantly reduced airway inflammation and...
A German-Serbian research project led by DZL scientist Dr. Stefan Hadzic is investigating how altered proteins contribute to COPD severity and progression – and how the resulting misguided immune response could be selectively blocked.
DZL researchers show that triple therapy can almost completely restore CFTR function in children with cystic fibrosis. The effect was particularly pronounced in younger children, highlighting the potential benefits of early treatment.
DZL scientist Prof. Dr. Matthias Griese has received the ERS Lifetime Achievement Award in Paediatrics 2026 for his outstanding contributions to paediatric pneumology and his longstanding commitment to children with rare and severe lung diseases.
Olivia Merkel, DZL PI and professor at Ludwig Maximilian University of Munich (LMU), has been awarded the UNIPRENEURS Award 2026. The award recognises professors who make an outstanding contribution to entrepreneurship and the translation of...
DZL PI Khodr Tello and his team have won first place in the Hessian start-up competition “Hessen Ideen.” Their award-winning medical software “Hemodynamix” aims to enable more precise cardiac diagnostics without additional invasive procedures.
Promising Phase 2 results from the international PHocus study point to the potential of the investigational inhaled drug mosliciguat for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
A new international guideline establishes common standards for personalized phage therapy in difficult-to-treat infections for the first time. The recommendations cover the selection and testing of suitable phages, manufacturing, quality control, application, and documentation.
Do changes in the blood explain why idiopathic pulmonary fibrosis progresses faster in some patients? DZL researchers uncover the role of an age-related phenomenon in the blood-forming system. At the center of the study is...
The Heidelberg-based PRiVENT project demonstrates a new approach to avoiding long-term invasive ventilation and out-of-hospital intensive care wherever possible — benefiting patients while offering the potential to save considerable resources within the healthcare system.
DZL researchers have elucidated a previously poorly understood mechanism of tumor regulation: itaconate, a metabolic intermediate produced by certain immune cells, can influence the metabolism of lung cancer cells and tumor-associated macrophages, thereby inhibiting tumor...
More than 680,000 blood and tissue samples, clinical data from over 20,000 patients, around 50 supported research projects each year and an average of 20 scientific publications: For 25 years, the Heidelberg Lung Biobank has...
